

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PALLA PHARMA LIMITED
ABN	26 107 872 453

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	JARROD RITCHIE
Date of last notice	13 DECEMBER 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	DIRECT & INDIRECT
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Jarrold Ritchie is a joint trustee and potential beneficiary of Ritchie Superannuation Fund
Date of change	18 November 2019
No. of securities held prior to change: Mr Jarrold Ritchie Mrs Catrina Ritchie & Mr Jarrold Ritchie Jarrold Ritchie & Catrina Ritchie as trustees for Ritchie Superannuation Fund	522,562 834 <u>986,555</u> <u>1,509,951</u>
Class	Ordinary Shares
Number acquired	603,981
Number disposed	NIL
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$422,787

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	
Mr Jarrod Ritchie	731,587
Mrs Catrina Ritchie & Mr Jarrod Ritchie	1,168
Jarrold Ritchie & Catrina Ritchie as trustees for Ritchie Superannuation Fund	<u>1,381,177</u>
	<u>2,113,932</u>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in non-renounceable entitlement offer announced to the market on 17 October 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only